Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma.

Kitamura H, Torigoe T, Hirohashi Y, Asanuma H, Inoue R, Nishida S, Tanaka T, Masumori N, Sato N, Tsukamoto T.

Virchows Arch. 2013 Jan;462(1):101-7. doi: 10.1007/s00428-012-1343-7. Epub 2012 Nov 20.

PMID:
23179762
2.

Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract.

Kitamura H, Torigoe T, Hirohashi Y, Asanuma H, Inoue R, Nishida S, Tanaka T, Fukuta F, Masumori N, Sato N, Tsukamoto T.

Mod Pathol. 2013 Jan;26(1):117-24. doi: 10.1038/modpathol.2012.139. Epub 2012 Aug 17.

3.

Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study.

Mathieu R, Klatte T, Margulis V, Karam JA, Rouprêt M, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Bensalah K, Lotan Y, Rink M, Kluth LA, Scherr DS, Robinson BD, Shariat SF.

Urol Oncol. 2015 Nov;33(11):495.e15-22. doi: 10.1016/j.urolonc.2015.06.016. Epub 2015 Jul 27.

PMID:
26228160
4.

Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer.

Bria E, Visca P, Novelli F, Casini B, Diodoro MG, Perrone-Donnorso R, Botti C, Sperduti I, Facciolo F, Milella M, Cecere FL, Cognetti F, Mottolese M.

Eur J Surg Oncol. 2008 May;34(5):593-8. Epub 2007 Aug 10.

PMID:
17693049
5.

Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma.

Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, Olson SJ, Andersen JJ, Shyr Y, Carbone DP, Johnson DH, Hallahan DE, Lu B.

Cancer. 2005 Apr 15;103(8):1685-92.

6.

High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer.

Erpolat OP, Gocun PU, Akmansu M, Karakus E, Akyol G.

Strahlenther Onkol. 2012 Mar;188(3):248-54. doi: 10.1007/s00066-011-0042-7. Epub 2012 Feb 8.

PMID:
22311150
7.

Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.

Fromont G, Rouprêt M, Amira N, Sibony M, Vallancien G, Validire P, Cussenot O.

Eur Urol. 2005 Nov;48(5):764-70. Epub 2005 Aug 1.

PMID:
16126329
8.

The prognostic significance of nuclear CSE1L in urinary bladder urothelial carcinomas.

Chang CC, Tai CJ, Su TC, Shen KH, Lin SH, Yeh CM, Yeh KT, Lin YM, Jiang MC.

Ann Diagn Pathol. 2012 Oct;16(5):362-8. doi: 10.1016/j.anndiagpath.2012.02.005. Epub 2012 Apr 2.

PMID:
22476051
9.

Lymphovascular invasion is independently associated with poor prognosis in patients with localized upper urinary tract urothelial carcinoma treated surgically.

Saito K, Kawakami S, Fujii Y, Sakura M, Masuda H, Kihara K.

J Urol. 2007 Dec;178(6):2291-6; discussion 2296. Epub 2007 Oct 22.

PMID:
17936818
10.

Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma.

Krabbe LM, Bagrodia A, Lotan Y, Gayed BA, Darwish OM, Youssef RF, John G, Harrow B, Jacobs C, Gaitonde M, Sagalowsky AI, Shariat SF, Kapur P, Margulis V.

J Urol. 2014 Jan;191(1):28-34. doi: 10.1016/j.juro.2013.07.012. Epub 2013 Jul 16.

PMID:
23871758
11.

Expression of HuR, COX-2, and survivin in lung cancers; cytoplasmic HuR stabilizes cyclooxygenase-2 in squamous cell carcinomas.

Kim GY, Lim SJ, Kim YW.

Mod Pathol. 2011 Oct;24(10):1336-47. doi: 10.1038/modpathol.2011.90. Epub 2011 May 13.

12.

Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.

Nakanishi K, Kawai T, Torikata C, Aurues T, Ikeda T.

Cancer. 1998 Feb 15;82(4):724-32.

PMID:
9477106
13.

Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker.

Saito T, Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, Hidaka T, Arita K, Kurisu K.

J Neurooncol. 2007 Apr;82(2):193-8. Epub 2006 Dec 7.

PMID:
17151933
14.

Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.

Grabowski P, Griss S, Arnold CN, Hörsch D, Göke R, Arnold R, Heine B, Stein H, Zeitz M, Scherübl H.

Neuroendocrinology. 2005;81(1):1-9. Epub 2005 Apr 4.

PMID:
15809513
15.

The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma.

Miyazaki Y, Kosaka T, Mikami S, Kikuchi E, Tanaka N, Maeda T, Ishida M, Miyajima A, Nakagawa K, Okada Y, Sato Y, Oya M.

Clin Cancer Res. 2012 Aug 1;18(15):4145-53. doi: 10.1158/1078-0432.CCR-12-0073. Epub 2012 Jun 6.

16.

Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Predictive value of nuclear versus cytoplasmic staining.

Skagias L, Politi E, Karameris A, Sambaziotis D, Archondakis A, Ntinis A, Moreas I, Vasou O, Koutselini H, Patsouris E.

Anticancer Res. 2009 Oct;29(10):4163-7.

17.

[Nuclear and cytoplasmic expressions of survivin in glioma and their prognostic value].

Pan Y, Hu WH, Xie D, Wu QL, Liu YH, Xiang J, Wu HX.

Zhonghua Yi Xue Za Zhi. 2007 Jan 30;87(5):325-9. Chinese.

PMID:
17456361
18.

Factors affecting the survival of patients treated by standard nephroureterectomy for transitional cell carcinoma of the upper urinary tract.

Ataus S, Onal B, Tunc B, Erozenci A, Cekmen A, Kural AR, Oner A.

Int Urol Nephrol. 2006;38(1):9-13.

PMID:
16502046
19.

[The apoptosis inhibitor survivin in transitional cell carcinoma of the urinary bladder].

Vol'pina OM, Zavalishina LE, Volkova TD, Akhidova EV, Koroev DO, Andreeva IuIu, Petrov AN, Frank GA.

Arkh Patol. 2011 Mar-Apr;73(2):8-10. Russian.

PMID:
21695980
20.

Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract.

Kikuchi E, Horiguchi Y, Nakashima J, Hatakeyama N, Matsumoto M, Nishiyama T, Murai M.

J Urol. 2005 Dec;174(6):2120-3; discussion 2124.

PMID:
16280740

Supplemental Content

Support Center